FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPRO	VAL
	OMB Number:	3235-0287
	Estimated average burde	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					ii Seciii	011 30(11) (JI LITE	invesiment C	onipany Act	01 1940							
1. Name and Address of Reporting Person * $\underline{LANGER\ ROBERT}$					2. Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [KALA]						(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)					
												X Directo	or		10% Ov	/ner	
(Last) (First) (Middle) C/O KALA PHARMACEUTICALS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/12/2018							Officer below)	(give title		Other (s below)	pecify	
				L													
100 BEAVER STREET, SUITE 201					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)											Line	•		_			
WALTH	AM M	ÍΑ	02453										iled by Mor	•	orting Person One Repon		
(City)	(S	tate)	(Zip)									reisoi					
		Tab	le I - Non-l	Derivativ	/e Se	curities	s Ac	quired, Di	sposed o	f, or Be	neficiall	y Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,			Code (Instr. 5)					s Formally (D) (ollowing (I) (I	Form (D) or	m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership	
							Code V	Amount	(A) or (D)	Price	Reported Transact (Instr. 3	tion(s)			(Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)			ransaction of De Code (Instr. Se Ac (A)		ive ies ed ed nstr.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ily	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$13.73	06/12/2018		A		12,960		(1)	06/11/2028	Common Stock	12,960	\$0	12,960)	D		

Explanation of Responses:

1. This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

/s/ Mary Reumuth, Attorney-in-Fact 06/14/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.